How does a ubiquitous protein in the central and peripheral nervous systems contribute to devastating neurodegenerative diseases? In the second installment of our blog series exploring the tau protein in health and disease, we will outline how pathological changes in tau regulation contribute to neurodegenerative disease while discussing ongoing research questions in the field.
Our last blog post introduced tau and its role in normal neurobiological processes: stabilizing microtubules, maintaining axonal integrity, supporting intracellular transport, and more. Tau exists in a diverse spectrum of isoforms and modification states that shifts across neuronal development and function. [1] Although the dynamic nature of tau confers versatility and flexibility in normal function, its regulation through post-translational modification (PTM) is a primary mechanism through which abnormal activity can drive pathology. [2]
Tau-related disease states, or tauopathies, are defined by abnormal aggregation and misfolding of the protein. [3] More than 26 distinct tauopathies have been identified to date, characterized by varied but overlapping symptoms and manifestations. While tau is soluble and stable under normal physiological conditions, a cascade of molecular processes contribute to its pathological transformation.
Tau’s affinity for microtubules is largely regulated by phosphorylation of specific amino acids. Positively charged lysine residues within the microtubule binding domain of tau drive affinity to negatively charged microtubules. However, dysregulation of phosphorylation disrupts this balance, with hyperphosphorylation being associated with neurodegenerative conditions. When serine/threonine residues within the protein are hyperphosphorylated, the charge balance is disrupted, which reduces tau’s affinity to microtubules and causes it to dissociate. [4] Once dissociated, tau becomes prone to misfolding and can self-assemble into oligomers, which can further aggregate into insoluble filaments that ultimately form neurofibrillary tangles (NFTs) and other intracellular inclusions. Several tau species with specific phosphorylation sites are recognized as biomarkers of neurodegenerative pathophysiology, particularly in Alzheimer’s disease (AD). Plasma and cerebrospinal fluid (CSF) levels of phosphorylated tau at Thr181 (p-tau181), Thr217 (p-tau217), and Thr231 (p-tau231) have high diagnostic accuracy for AD in patients with cognitive impairment. [5] Additionally, p-tau212 and p-tau205 are increasingly studied as markers of specific stages of AD neuropathology and cognitive decline. [6,7]
While NFTs were long believed to be the primary driver of tau-related neurotoxicity, these soluble tau oligomers are also increasingly recognized as highly neurotoxic intermediates. [8] Growing evidence suggests that the formation of tau oligomers may play a more direct role in tau-related neurotoxicity and neurodegeneration than the presence of NFTs themselves, which may in fact be evidence of failed cytoprotective efforts in response to abnormal tau accumulation. [9,10] Emerging evidence also suggests that pathological tau fibrils can spread between cells in a prion-like cascade, seeding the misfolding and aggregation of tau in neighboring brain regions. [11] This progressive accumulation of misfolded tau impairs neuronal function through multiple mechanisms, including disruption of axonal transport, mitochondrial dysfunction, synaptic loss, neuroinflammation, and eventual neuronal death.
Although this general process of tau aggregation underlies the broad spectrum of tauopathies, differences in tau isoform composition, filament structure, affected cell types, and patterns of brain distribution contribute to the distinct clinical and pathological features observed across neurodegenerative diseases. [12] For example:
Thus, while pathological tau aggregation represents a common molecular hallmark across tauopathies, disease-specific conformations and distributions of aggregated tau give rise to diverse neurodegenerative conditions with distinct clinical presentations and rates of progression.
Not all changes in tau are equally informative for understanding neurodegenerative disease. While measurements of total tau can provide a general indication of neuronal injury or protein abundance, they offer limited insight into the specific molecular processes that drive pathology. Disease relevance arises from hyperphosphorylation and other PTMs, conformational alterations, oligomerization, aggregation, and propagation. [17] As a result, research and biomarker identification efforts increasingly focus on quantifying specific pathological tau species, such as p-tau217 in AD, as well as relative concentrations of p-tau species and total tau. [18] Endpoints such as phosphorylation at specific disease-associated epitopes, conformationally altered tau, soluble oligomers, seeding-competent species, and fibrillar aggregates are considered more informative than total tau because they more closely reflect the mechanisms underlying disease initiation and progression. [19]
Despite substantial advances in the field, several fundamental questions regarding tau pathology remain unresolved. One major area of investigation concerns the factors that induce pathological PTMs, particularly hyperphosphorylation and other modifications that destabilize tau and promote aggregation. It is also unclear what drives tau misfolding in vivo and why certain pathological conformations emerge in specific disease contexts but fail to arise in others. Increasing evidence suggests that distinct tau strains may underlie the heterogeneity observed across tauopathies, yet the mechanisms governing their formation and spread remain poorly understood. [20] Equally important is determining more clearly how tau aggregation ultimately causes neurodegeneration. While NFTs are a hallmark of disease, the relative contributions of various tau species, as well as their overlap with synaptic dysfunction, neuroinflammation, mitochondrial impairment, and other pathogenic processes, continue to be actively investigated. [21] A more sophisticated understanding of these factors will be instrumental in identifying and pursuing viable therapeutic targets.
Recent technological advances have significantly improved our understanding of disease-relevant tau biology. Cryogenic electron microscopy (cryo-EM) has revolutionized the field by revealing that tau filaments adopt distinct structural folds in different tauopathies, providing direct evidence that tau pathology is structurally diverse across diseases. However, cryo-EM primarily resolves the highly ordered fibrillar core of aggregated tau, while much of the surrounding protein remains unresolved as a dynamic “fuzzy coat.” [22] Moreover, pathological tau exists as a heterogeneous continuum of species, the intricacies of which are difficult to characterize using structural approaches alone.
These limitations underscore the need for tools capable of detecting and distinguishing specific disease-relevant tau species within complex biological samples, including blood, cerebrospinal fluid (CSF), and tissue. In particular, highly sensitive and selective antibodies have become indispensable for interrogating tau biology, enabling the detection of discrete PTMs, conformational states, aggregation intermediates, and pathological inclusions that may be inaccessible to other techniques. [23] As researchers seek to understand which tau species drive pathological processes, antibodies with exceptional specificity and sensitivity will be critical for elucidating disease mechanisms, identifying clinically relevant biomarkers, and evaluating therapeutic strategies targeting the most pathogenic forms of tau.
Although tau has been studied for decades, its role in neurodegenerative disease remains remarkably complex. What was once viewed as a relatively straightforward process of protein aggregation is now understood to involve a dynamic and heterogeneous spectrum of tau species, conformations, post-translational modifications, and pathological mechanisms that vary across diseases and stages of progression. As a result, understanding tau pathology requires moving beyond measurements of total tau and toward a more nuanced examination of the specific molecular changes that drive dysfunction, propagation, and neurodegeneration.
At the same time, many of the field’s most important questions remain unanswered. Addressing these challenges will require not only continued scientific innovation, but also highly sensitive and specific research tools capable of detecting subtle yet biologically meaningful changes. High-quality antibodies and other advanced detection tools will play an increasingly important role in identifying disease-relevant tau species, accelerating biomarker discovery, and enabling the development of more targeted therapeutic strategies. By equipping researchers with the tools needed to interrogate tau at greater resolution, the scientific community can continue making progress toward unraveling the complexities of tauopathies and advancing new approaches to diagnose, monitor, and ultimately treat these devastating neurodegenerative diseases.
Aviva Systems Biology is dedicated to supporting neuroscience and neurodegeneration research advancement with rigorously validated high-quality antibodies and reagents. Our total and phospho-tau ELISA kits offer unmatched sensitivity and precision to empower your tau research. To learn more about investigating tau and other neurodegenerative disease markers, download our eBook, ‘Neurodegenerative Disease Markers and Detection Methods.’
References
[1] Barbier, Pauline, et al. “Role of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects.” Frontiers in Aging Neuroscience, vol. 11, 2019, article 204. https://doi.org/10.3389/fnagi.2019.00204.
[2] Yang, Jiakai et al. “Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review.” Molecules (Basel, Switzerland) vol. 29,12 2812. 13 Jun. 2024, https://doi:10.3390/molecules29122812.
[3] Zheng, Huiting, et al. “The Enigma of Tau Protein Aggregation: Mechanistic Insights and Future Challenges.” International Journal of Molecular Sciences, vol. 25, no. 9, 2024, p. 4969, https://doi.org/10.3390/ijms25094969.
[4] Lim, Sungsu, et al. “Cell-Based Models to Investigate Tau Aggregation.” Computational and Structural Biotechnology Journal, vol. 12, 2014, pp. 7–13, https://doi.org/10.1016/j.csbj.2014.09.011.
[5] Milà-Alomà, Marta, et al. “Plasma p-tau231 and p-tau217 as State Markers of Amyloid-β Pathology in Preclinical Alzheimer’s Disease.” Nature Medicine, vol. 28, no. 9, 2022, pp. 1797–1801, https://doi.org/10.1038/s41591-022-01925-w.
[6] Kac, Przemysław R., et al. “Plasma p-tau212 Identifies Cognitively Unimpaired Individuals with Emerging Amyloid-β Pathology.” Journal of Neurology, vol. 273, no. 1, 2026, article 48, https://doi.org/10.1007/s00415-025-13572-5.
[7] Lantero-Rodriguez, Juan, et al. “CSF p-tau205: A Biomarker of Tau Pathology in Alzheimer’s Disease.” Acta Neuropathologica, vol. 147, no. 1, 2024, article 12, https://doi.org/10.1007/s00401-023-02659-w.
[8] Niewiadomska, Grazyna, et al. “Tau Oligomers Neurotoxicity.” Life, vol. 11, no. 1, 2021, article 28, https://doi.org/10.3390/life11010028.
[9] Gendreau, Kerry L., and Garth F. Hall. “Tangles, Toxicity, and Tau Secretion in AD—New Approaches to a Vexing Problem.” Frontiers in Neurology, vol. 4, 2013, article 160, https://doi.org/10.3389/fneur.2013.00160.
[10] Ding, Huiping, and Gail V. W. Johnson. “The Last Tangle of Tau.” Journal of Alzheimer’s Disease, vol. 14, no. 4, 2008, pp. 441–447, https://doi.org/10.3233/JAD-2008-14413.
[11] Van Alstyne, Meaghan, et al. “Diverse Influences on Tau Aggregation and Implications for Disease Progression.” Genes & Development, vol. 39, nos. 9–10, 2025, pp. 555–581, https://doi.org/10.1101/gad.352551.124.
[12] Duquette, Antoine, et al. “Similarities and Differences in the Pattern of Tau Hyperphosphorylation in Physiological and Pathological Conditions: Impacts on the Elaboration of Therapies to Prevent Tau Pathology.” Frontiers in Neurology, vol. 11, 2021, article 607680, https://doi.org/10.3389/fneur.2020.607680.
[13] Nelson, Peter T., et al. “Correlation of Alzheimer Disease Neuropathologic Changes with Cognitive Status: A Review of the Literature.” Journal of Neuropathology & Experimental Neurology, vol. 71, no. 5, 2012, pp. 362–381, https://doi.org/10.1097/NEN.0b013e31825018f7.
[14] VandeVrede, Lawren, et al. “Four-Repeat Tauopathies: Current Management and Future Treatments.” Neurotherapeutics, vol. 17, no. 4, 2020, pp. 1563–1581, https://doi.org/10.1007/s13311-020-00888-5.
[15] Zhang, Yi, et al. “Tauopathies: New Perspectives and Challenges.” Molecular Neurodegeneration, vol. 17, no. 1, 2022, article 28, https://doi.org/10.1186/s13024-022-00533-z.
[16] McKee, Ann C., et al. “The Neuropathology of Chronic Traumatic Encephalopathy.” Brain Pathology, vol. 25, no. 3, 2015, pp. 350–364, https://doi.org/10.1111/bpa.12248.
[17] Schraen-Maschke, Susanna, et al. “Tau as a Biomarker of Neurodegenerative Diseases.” Biomarkers in Medicine, vol. 2, no. 4, 2008, pp. 363–384, https://doi.org/10.2217/17520363.2.4.363.
[18] Montoliu-Gaya, Laia, et al. “Plasma Tau Biomarkers for Biological Staging of Alzheimer’s Disease.” Nature Aging, vol. 5, no. 11, 2025, pp. 2297–2308, https://doi.org/10.1038/s43587-025-00951-w.
[19] Vacchi, Elena, et al. “Tau Biomarkers for Neurodegenerative Diseases: Current State and Perspectives.” Parkinsonism & Related Disorders, vol. 134, 2025, article 107772, https://doi.org/10.1016/j.parkreldis.2025.107772.
[20] Tabeshmehr, Parisa, and Eftekhar Eftekharpour. “Tau; One Protein, So Many Diseases.” Biology, vol. 12, no. 2, 2023, p. 244, https://doi.org/10.3390/biology12020244.
[21] Laurent, Cyril, et al. “Tau and Neuroinflammation: What Impact for Alzheimer’s Disease and Tauopathies?” Biomedical Journal, vol. 41, no. 1, 2018, pp. 21–33, https://doi.org/10.1016/j.bj.2018.01.003.
[22] Scheres, Sjors H. W., et al. “Cryo-EM Structures of Tau Filaments.” Current Opinion in Structural Biology, vol. 64, 2020, pp. 17–25, https://doi.org/10.1016/j.sbi.2020.05.011.
[23] Ellis, Michael J., et al. “Identification of High-Performing Antibodies for the Reliable Detection of Tau Proteoforms by Western Blotting and Immunohistochemistry.” Acta Neuropathologica, vol. 147, no. 1, 2024, article 87, https://doi.org/10.1007/s00401-024-02729-7.